Drugs / Anbal-cel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07062627 | Nov 2025 → Dec 2026 expected | diffuse large B-cell lymphoma, primary central nervous system lymphoma | Hyungwoo Cho | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anbal-cel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07062627 ↗ |
| Known as | Anbalcabtagene autoleucel | “Anbalcabtagene autoleucel (Anbal-cel) is an investigational autologous anti-CD19 CAR-T cell product” NCT07062627 ↗ |
| Action | Deplete | “Upon CD19 engagement, Anbal-cel forms an immunological synapse and triggers effector functions, including proliferation, cytokine secretion (e.g., IFN-γ, IL-6, TNF-α, GM-CSF),...” NCT07062627 ↗ |
| Modality | Cell therapy | “Anbalcabtagene autoleucel (Anbal-cel) is an investigational autologous anti-CD19 CAR-T cell product” NCT07062627 ↗ |
| Route | Intravenous | “Anbal-cel will be administered as a single intravenous infusion on Day 1 within 30 minutes of thawing” NCT07062627 ↗ |
| Target | CD19 | “incorporating a CD19-specific scFv” NCT07062627 ↗ |